ArticleJournal of nanobiotechnology2017
Multi-walled carbon nanotubes functionalized with recombinant Dengue virus 3 envelope proteins induce significant and specific immune responses in mice.
Article in Journal of nanobiotechnology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Nanoparticle vaccine formulations for dengue virus.RSC pharmaceutics · 2026Review
- Modeling and Molecular Dynamics Studies of Flavone-DENV E-3 Protein-SWCNT Interaction at the Flavonoid Binding Sites.Viruses · 2025Article
- Engineering carbon nanotubes for sensitive viral detection.Trends in analytical chemistry : TRAC · 2022Review
- Coronavirus and Carbon Nanotubes: Seeking Immunological Relationships to Discover Immunotherapeutic Possibilities.International journal of nanomedicine · 2022Review
- Light- and Melanin Nanoparticle-Induced Cytotoxicity in Metastatic Cancer Cells.Pharmaceutics · 2021Article
- Zoonotic vaccinia virus strains belonging to different genetic clades exhibit immunomodulation abilities that are proportional to their virulence.Virology journal · 2021Article
- Nanotechnology-based antiviral therapeutics.Drug delivery and translational research · 2021Review
- Nanoparticles as Vaccines to Prevent Arbovirus Infection: A Long Road Ahead.Pathogens (Basel, Switzerland) · 2021Review
- Advances and Perspectives in the Use of Carbon Nanotubes in Vaccine Development.International journal of nanomedicine · 2021Review
- Challenges in Dengue Vaccines Development: Pre-existing Infections and Cross-Reactivity.Frontiers in immunology · 2020Review
- Long-Term Protection Elicited by a DNA Vaccine Candidate Expressing the prM-E Antigen of Dengue Virus Serotype 3 in Mice.Frontiers in cellular and infection microbiology · 2020Article
- Designing inorganic nanomaterials for vaccines and immunotherapies.Nano today · 2019Article
- Synthesis of Gold Nanoparticles Decorated with Multiwalled Carbon Nanotubes (Au-MWCNTs) via Cysteaminium Chloride Functionalization.Scientific reports · 2019Article
- Bionanotechnology for vaccine design.Current opinion in biotechnology · 2018Review
- Development of Peptide Vaccines in Dengue.Current pharmaceutical design · 2018Review
- Raman spectroscopy-based identification of toxoid vaccine products.NPJ vaccines · 2018Article
- Recent Developments in Recombinant Protein-Based Dengue Vaccines.Frontiers in immunology · 2018Review
- A carbon nanotube-gemcitabine-lentinan three-component composite for chemo-photothermal synergistic therapy of cancer.International journal of nanomedicine · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDengue is the most prevalent arthropod-borne viral disease in the world. In this article we present results on the development, characterization and immunogenic evaluation of an alternative vaccine candidate against Dengue.
methodsThe MWNT-DENV3E nanoconjugate was developed by covalent functionalization of carboxylated multi-walled carbon nanotubes (MWNT) with recombinant dengue envelope (DENV3E) proteins. The recombinant antigens were bound to the MWNT using a diimide-activated amidation process and the immunogen was characterized by TEM, AFM and Raman Spectroscopy. Furthermore, the immunogenicity of this vaccine candidate was evaluated in a murine model.
resultsImmunization with MWNT-DENV3E induced comparable IgG responses in relation to the immunization with non-conjugated proteins; however, the inoculation of the nanoconjugate into mice generated higher titers of neutralizing antibodies. Cell-mediated responses were also evaluated, and higher dengue-specific splenocyte proliferation was observed in cell cultures derived from mice immunized with MWNT-DENV3E when compared to animals immunized with the non-conjugated DENV3E.
conclusionsDespite the recent licensure of the CYD-TDV dengue vaccine in some countries, results from the vaccine's phase III trial have cast doubts about its overall efficacy and global applicability. While questions about the effectiveness of the CYD-TDV vaccine still lingers, it is wise to keep at hand an array of vaccine candidates, including alternative non-classical approaches like the one presented here.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.